Evidence map›Paper›PMID 42787309›Full record

ArticleJournal of pharmaceutical analysis2026

Genipin induces liver injury by disrupting the CPS1-regulated urea cycle and redox homeostasis.

Hongzhan Xu, Xinhui Huang, Yujia Zhang, Shilin Gong, Yusha Luo, Yichao Fang, Xiaolan Hu, Miaomiao Luo, Yujia Zhai, Fangyuan Gao and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hongzhan XuSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Xinhui HuangSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Yujia ZhangSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Shilin GongSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Yusha LuoSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Yichao FangDepartment of Pharmacy, The First Navy Hospital of Southern Theater Command, Zhanjiang, Guangdong, 524005, China.
Xiaolan HuInstitute of Mass Spectrometry and Atmospheric Environment, Guangdong Provincial Key Laboratory of Speed Capability Research, Jinan University, Guangzhou, 510632, China.
Miaomiao LuoDepartment of Pharmacy, Shanghai Xuhui District Central Hospital, Shanghai, 200020, China.
Yujia ZhaiNaval Medical Center, Second Military Medical University, Shanghai, 200433, China.
Fangyuan GaoDepartment of Health Toxicology, Faculty of Naval Medicine, Naval Medical University, Shanghai, 200433, China.
Xinglong ChenSchool of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicine Utilization, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Rongping ZhangSchool of Chinese Materia Medica and Yunnan Key Laboratory of Southern Medicine Utilization, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Longshan ZhaoSchool of Pharmacy, Shenyang Pharaceutical University, Shenyang, 117004, China.
Yong WangSchool of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.
Jian-Lin WuState Key Laboratory for Quality Research of Chinese Medicines, Macau University of Science and Technology, Taipa, Macau SAR, 999078, China.
Xin ZhangDepartment of Gastrointestinal Surgery, Changzheng Hospital, Naval Medical University, Shanghai, 200003, China.
Huiqing LiangHepatology Unit, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, Fujian, 361015, China.
Jun WenSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.
Tingting ZhouSchool of Pharmacy, Second Military Medical University, Shanghai, 200433, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genipin (GP) is the key metabolite of geniposide (GE), the primary active component of the traditional Chinese medicine Gardeniae Fructus. Its hepatotoxicity poses a potential risk to safe clinical administration, while its core pathophysiological mechanism remains unclear. This study systematically elucidated the molecular mechanisms of GP-induced hepatotoxicity through integrated multi-omics and functional validation. GP treatment induced significant liver damage and oxidative stress in rats, characterized by elevated serum transaminases (alanine aminotransferase (ALT) increased by approximately 63.5-fold; aspartate aminotransferase (AST) by 18.6-fold), an approximately 1.8-fold decrease in superoxide dismutase (SOD) activity, and an approximately 10-fold accumulation of malondialdehyde (MDA) (all

Indexed as

Carbamoyl phosphate synthetase 1Gardeniae FructusGenipinUrea cycle

Identifiers

PMID42787309
PMCPMC13601060

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.